These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

351 related items for PubMed ID: 20630061

  • 1. Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies.
    Javle MM, Shroff RT, Xiong H, Varadhachary GA, Fogelman D, Reddy SA, Davis D, Zhang Y, Wolff RA, Abbruzzese JL.
    BMC Cancer; 2010 Jul 14; 10():368. PubMed ID: 20630061
    [Abstract] [Full Text] [Related]

  • 2. A phase II study of temsirolimus and erlotinib in patients with recurrent and/or metastatic, platinum-refractory head and neck squamous cell carcinoma.
    Bauman JE, Arias-Pulido H, Lee SJ, Fekrazad MH, Ozawa H, Fertig E, Howard J, Bishop J, Wang H, Olson GT, Spafford MJ, Jones DV, Chung CH.
    Oral Oncol; 2013 May 14; 49(5):461-7. PubMed ID: 23384718
    [Abstract] [Full Text] [Related]

  • 3. Phase II study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced pancreatic cancer.
    Kordes S, Klümpen HJ, Weterman MJ, Schellens JH, Richel DJ, Wilmink JW.
    Cancer Chemother Pharmacol; 2015 Jun 14; 75(6):1135-41. PubMed ID: 25822310
    [Abstract] [Full Text] [Related]

  • 4. mTOR inhibition induces EGFR feedback activation in association with its resistance to human pancreatic cancer.
    Wei F, Zhang Y, Geng L, Zhang P, Wang G, Liu Y.
    Int J Mol Sci; 2015 Feb 03; 16(2):3267-82. PubMed ID: 25654224
    [Abstract] [Full Text] [Related]

  • 5. Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors.
    Buck E, Eyzaguirre A, Brown E, Petti F, McCormack S, Haley JD, Iwata KK, Gibson NW, Griffin G.
    Mol Cancer Ther; 2006 Nov 03; 5(11):2676-84. PubMed ID: 17121914
    [Abstract] [Full Text] [Related]

  • 6. Stromal cell-derived factor 1α mediates resistance to mTOR-directed therapy in pancreatic cancer.
    Weekes CD, Song D, Arcaroli J, Wilson LA, Rubio-Viqueira B, Cusatis G, Garrett-Mayer E, Messersmith WA, Winn RA, Hidalgo M.
    Neoplasia; 2012 Aug 03; 14(8):690-701. PubMed ID: 22952422
    [Abstract] [Full Text] [Related]

  • 7. Cotargeting of epidermal growth factor receptor and PI3K overcomes PI3K-Akt oncogenic dependence in pancreatic ductal adenocarcinoma.
    Wong MH, Xue A, Julovi SM, Pavlakis N, Samra JS, Hugh TJ, Gill AJ, Peters L, Baxter RC, Smith RC.
    Clin Cancer Res; 2014 Aug 01; 20(15):4047-58. PubMed ID: 24895459
    [Abstract] [Full Text] [Related]

  • 8. Rationale and protocol of the MetNET-1 trial, a prospective, single center, phase II study to evaluate the activity and safety of everolimus in combination with octreotide LAR and metformin in patients with advanced pancreatic neuroendocrine tumors.
    Pusceddu S, de Braud F, Concas L, Bregant C, Leuzzi L, Formisano B, Buzzoni R.
    Tumori; 2014 Aug 01; 100(6):e286-9. PubMed ID: 25688512
    [Abstract] [Full Text] [Related]

  • 9. Multi-level targeting of the phosphatidylinositol-3-kinase pathway in non-small cell lung cancer cells.
    Zito CR, Jilaveanu LB, Anagnostou V, Rimm D, Bepler G, Maira SM, Hackl W, Camp R, Kluger HM, Chao HH.
    PLoS One; 2012 Aug 01; 7(2):e31331. PubMed ID: 22355357
    [Abstract] [Full Text] [Related]

  • 10. PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors.
    Meric-Bernstam F, Akcakanat A, Chen H, Do KA, Sangai T, Adkins F, Gonzalez-Angulo AM, Rashid A, Crosby K, Dong M, Phan AT, Wolff RA, Gupta S, Mills GB, Yao J.
    Clin Cancer Res; 2012 Mar 15; 18(6):1777-89. PubMed ID: 22422409
    [Abstract] [Full Text] [Related]

  • 11. A phase Ib study of combined VEGFR and mTOR inhibition with vatalanib and everolimus in patients with advanced renal cell carcinoma.
    Bitting RL, Healy P, Creel PA, Turnbull J, Morris K, Wood SY, Hurwitz HI, Starr MD, Nixon AB, Armstrong AJ, George DJ.
    Clin Genitourin Cancer; 2014 Aug 15; 12(4):241-50. PubMed ID: 24685058
    [Abstract] [Full Text] [Related]

  • 12. Phosphorylation of mTOR and S6RP predicts the efficacy of everolimus in patients with metastatic renal cell carcinoma.
    Li S, Kong Y, Si L, Chi Z, Cui C, Sheng X, Guo J.
    BMC Cancer; 2014 May 28; 14():376. PubMed ID: 24886512
    [Abstract] [Full Text] [Related]

  • 13. Survival benefit with proapoptotic molecular and pathologic responses from dual targeting of mammalian target of rapamycin and epidermal growth factor receptor in a preclinical model of pancreatic neuroendocrine carcinogenesis.
    Chiu CW, Nozawa H, Hanahan D.
    J Clin Oncol; 2010 Oct 10; 28(29):4425-33. PubMed ID: 20823411
    [Abstract] [Full Text] [Related]

  • 14. Phase I safety and pharmacokinetic study of the PI3K/mTOR inhibitor SAR245409 (XL765) in combination with erlotinib in patients with advanced solid tumors.
    Jänne PA, Cohen RB, Laird AD, Macé S, Engelman JA, Ruiz-Soto R, Rockich K, Xu J, Shapiro GI, Martinez P, Felip E.
    J Thorac Oncol; 2014 Mar 10; 9(3):316-23. PubMed ID: 24496004
    [Abstract] [Full Text] [Related]

  • 15. Different patterns of Akt and ERK feedback activation in response to rapamycin, active-site mTOR inhibitors and metformin in pancreatic cancer cells.
    Soares HP, Ni Y, Kisfalvi K, Sinnett-Smith J, Rozengurt E.
    PLoS One; 2013 Mar 10; 8(2):e57289. PubMed ID: 23437362
    [Abstract] [Full Text] [Related]

  • 16. Phase I study evaluating the combination of lapatinib (a Her2/Neu and EGFR inhibitor) and everolimus (an mTOR inhibitor) in patients with advanced cancers: South West Oncology Group (SWOG) Study S0528.
    Gadgeel SM, Lew DL, Synold TW, LoRusso P, Chung V, Christensen SD, Smith DC, Kingsbury L, Hoering A, Kurzrock R.
    Cancer Chemother Pharmacol; 2013 Nov 10; 72(5):1089-96. PubMed ID: 24057042
    [Abstract] [Full Text] [Related]

  • 17. Synergistic effects of erlotinib and everolimus on bronchial carcinoids and large-cell neuroendocrine carcinomas with activated EGFR/AKT/mTOR pathway.
    Bago-Horvath Z, Sieghart W, Grusch M, Lackner A, Hayden H, Pirker C, Komina O, Węsierska-Gądek J, Haitel A, Filipits M, Berger W, Schmid K.
    Neuroendocrinology; 2012 Nov 10; 96(3):228-37. PubMed ID: 22378048
    [Abstract] [Full Text] [Related]

  • 18. PTEN deficiency is associated with reduced sensitivity to mTOR inhibitor in human bladder cancer through the unhampered feedback loop driving PI3K/Akt activation.
    Seront E, Pinto A, Bouzin C, Bertrand L, Machiels JP, Feron O.
    Br J Cancer; 2013 Sep 17; 109(6):1586-92. PubMed ID: 23989949
    [Abstract] [Full Text] [Related]

  • 19. The search continues: looking for predictive biomarkers for response to mammalian target of rapamycin inhibition in endometrial cancer.
    Meyer LA, Slomovitz BM, Djordjevic B, Westin SN, Iglesias DA, Munsell MF, Jiang Y, Schmandt R, Broaddus RR, Coleman RL, Galbincea JM, Lu KH.
    Int J Gynecol Cancer; 2014 May 17; 24(4):713-7. PubMed ID: 24651628
    [Abstract] [Full Text] [Related]

  • 20. Phase II Study of BEZ235 versus Everolimus in Patients with Mammalian Target of Rapamycin Inhibitor-Naïve Advanced Pancreatic Neuroendocrine Tumors.
    Salazar R, Garcia-Carbonero R, Libutti SK, Hendifar AE, Custodio A, Guimbaud R, Lombard-Bohas C, Ricci S, Klümpen HJ, Capdevila J, Reed N, Walenkamp A, Grande E, Safina S, Meyer T, Kong O, Salomon H, Tavorath R, Yao JC.
    Oncologist; 2018 Jul 17; 23(7):766-e90. PubMed ID: 29242283
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.